Amphotericin B: Polyene Antifungal Antibiotic for Advanced Fungal Infection Research

Executive Summary: Amphotericin B is an amphipathic polyene antifungal antibiotic produced by Streptomyces nodosus and is widely used in experimental fungal infection research (APExBIO B1885). Its primary mode of action is mediated by selective binding to ergosterol in fungal membranes, leading to pore formation and disruption of cellular homeostasis (Mechanistic Insights). The compound displays nanomolar to sub-micromolar IC₅₀ values (0.028–0.290 μg/mL) in vitro, making it highly effective against clinically relevant fungal species. Amphotericin B also modulates immune signaling via TLR2 and CD14, triggering NF-κB activation and cytokine release. Its toxicity profile, linked to cholesterol interaction in mammalian cells, restricts its use to research settings and mandates careful workflow integration (APExBIO).

Biological Rationale

Amphotericin B addresses a critical need in fungal infection research due to the increasing incidence of life-threatening mycoses and the emergence of antifungal resistance. Its unique mechanism—targeting membrane sterols—circumvents common resistance mechanisms associated with azoles and echinocandins (Advancing Fungal Infection Research). The compound's immunomodulatory effects, including activation of TLR2/CD14-mediated signaling and NF-κB pathway, make it valuable for studying host-pathogen interactions and inflammatory responses. Importantly, Amphotericin B's efficacy in prion disease models (transmissible spongiform encephalopathies, TSSE) has broadened its utility beyond antifungal applications (Mechanistic Insights and New Frontiers).

Mechanism of Action of Amphotericin B

Amphotericin B is an amphipathic polyene antibiotic (C₄₇H₇₃NO₁₇, MW 924.08) that integrates into fungal membranes by selectively binding to ergosterol. This interaction induces the assembly of aqueous pores, increasing permeability to cations and anions and leading to loss of ion gradients, cell lysis, and death (Mechanistic Insights). In mammalian cells, partial affinity for cholesterol results in off-target toxicity, including nephrotoxicity and infusion reactions (Transforming Research Workflows). On immune cells expressing TLR2 and CD14, Amphotericin B triggers NF-κB translocation and promotes inflammatory cytokine secretion (Mechanistic Insights and New Frontiers).

Evidence & Benchmarks

• Amphotericin B demonstrates potent in vitro antifungal activity, with IC₅₀ values from 0.028 to 0.290 μg/mL against Candida and Aspergillus spp. (APExBIO B1885).
• Mechanistically, it forms membrane pores by binding ergosterol, disrupting ion homeostasis and leading to fungal cell death (Mechanistic Insights).
• Amphotericin B activates TLR2 and CD14 signaling in macrophages, leading to NF-κB-dependent cytokine release (TSSE Model Review).
• In prion disease models, in vivo administration reduces prion protein accumulation and prolongs survival time in animals (Polyene Antifungal for Advanced Research).
• Amphotericin B is soluble at ≥46.2 mg/mL in DMSO, but insoluble in water or ethanol; stock solutions should be stored below −20°C and not kept long-term when dissolved (APExBIO B1885).

Applications, Limits & Misconceptions

Amphotericin B is utilized in:

• Fungal infection studies—as a gold-standard control for antifungal susceptibility and resistance research.
• Immune signaling models—to probe TLR2/CD14-mediated activation and cytokine release.
• Prion disease (TSSE) models—to assess effects on prion protein deposition and host survival.
• Biofilm resistance studies—as a comparator in evaluating anti-biofilm agents (Advancing Fungal Infection Research).

Unlike many antifungals, it is not suitable for direct clinical use in its research form due to toxicity and formulation constraints. This article clarifies and extends prior reviews by detailing quantitative solubility, storage, and immune activation parameters, complementing existing mechanistic summaries (Mechanistic Insights).

Common Pitfalls or Misconceptions

• Not water-soluble: Amphotericin B is insoluble in water; DMSO is required for stock solution preparation (APExBIO).
• Not a clinical formulation: Research-grade Amphotericin B (SKU B1885) is for laboratory use only, not for medical or diagnostic applications.
• Long-term storage: Stock solutions should not be stored long-term after dissolution; degradation may occur even at −20°C.
• Non-specific membrane effects: At high concentrations, Amphotericin B can disrupt mammalian cell membranes due to cholesterol binding.
• Not effective against all biofilms: Fungal biofilms may still display partial resistance due to matrix protection mechanisms (Advancing Fungal Infection Research).

Workflow Integration & Parameters

For experimental applications, stock solutions of Amphotericin B are prepared at ≥46.2 mg/mL in DMSO. Working concentrations typically range from 1 to 4 μg/mL in cell-based assays (APExBIO). Solutions should be freshly prepared and stored below −20°C. Shipping is performed on blue ice to maintain compound integrity. Researchers should use appropriate controls to distinguish between antifungal and cytotoxic effects, especially in co-culture models with mammalian cells. For in vivo studies, dosing and formulation must be optimized to minimize host toxicity and maximize target engagement (Transforming Fungal Infection Research Workflows—this article details new quality control parameters and storage guidelines beyond prior workflow guides).

Conclusion & Outlook

Amphotericin B remains a cornerstone tool in fungal infection and immune signaling research, offering robust efficacy and mechanistic clarity. The APExBIO B1885 product enables reproducible, high-fidelity experiments when deployed with defined parameters. Future research may further refine its utility in biofilm and prion models, while ongoing advances in formulation seek to mitigate toxicity and broaden applications (Mechanistic Insights and New Frontiers).